The following stories appear in full on Today's Vidyya Medical News Service Web site.
Reminyl® (galantamine hydrobromide) - a new treatment for mild to moderate Alzheimer's disease derived from the bulbs of daffodils - was approved Feb. 28, 2001 by the U.S. Food and Drug Administration (FDA). Data from four placebo-controlled, double-blind clinical trials involving more than 2,650 patients show that Reminyl can have a beneficial effect on patients' daily function and ability to think. To be available by prescription in May, Reminyl was developed by the Janssen Research Foundation under a co-development and licensing agreement with the UK-based Shire Pharmaceuticals Group plc.
For more information: Reminyl, New Treatment For Alzheimer's Disease, Receives FDA Approval
Reminyl will be available in 4 mg, 8 mg or 12 mg tablets. The approved product labeling recommends that physicians start by prescribing 8 mg of Reminyl per day (in two divided doses), then increase the dose to 16 mg after at least four weeks. Physicians have the flexibility to increase the daily dose to 24 mg after an additional four weeks. Get the full prescribing information in today's issue.
For more information: Prescribing Information: Reminyl (Galantamine Hydrobromide)
Patients and their physicians told Congress on Friday that reforms must be made to the way the Health Care Financing Administration (HCFA) makes Medicare coverage and payment decisions to ensure that elderly and disabled Americans have timely access to the latest advances in medical technology. The joint hearing of the House Commerce Subcommittee on Health and Subcommittee on Oversight & Investigations entitled "Patients First: A 21st Century Promise to Ensure Quality and Affordable Health Coverage," focused specifically on improving patients' access to new technologies in the Medicare program.
For more information: Patients & Physicians Testify: Medicare Reforms Needed To Ensure Access To Lifesaving Medical Technology
Findings from a study appearing in the March issue of Ophthalmology, the journal of the American Academy of Ophthalmology, indicate more than one third of people with diabetes do not adhere to vision care guidelines established by both the Academy and the American Diabetes Association.
For more information: Diabetics Not Receiving Adequate Opthalmological Care
A new blood test for Lyme disease may provide a more accurate method for detecting the tick-borne illness, particularly in its early stages when current tests may not yield an accurate diagnosis. A researcher from The Children's Hospital of Philadelphia has used a method that detects telltale proteins that often remain hidden from routine blood tests for Lyme disease.
For more information: More Accurate Test For Lyme Disease Announced By Researcher At The Children's Hospital Of Philadelphia
Today's Vidyya articles are:
As always, we hope you enjoy the issue.